<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>35-AMPHOTERICIN-B.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMPHOTERICIN B " rxcui="732">
<ATC code="J02AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="AMINOGLYCOSIDES " code="J01GB-001" /></DRUG2>
<DESCRIPTION>With the amphotericin B administered intravenously: increased risk of nephrotoxicity</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>35-AMPHOTERICIN-B.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMPHOTERICIN B " rxcui="732">
<ATC code="J02AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the amphotericin B administered intravenously:

greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances).</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>35-AMPHOTERICIN-B.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMPHOTERICIN B " rxcui="732">
<ATC code="J02AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
<ATC code="L04AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the amphotericin B administered intravenously: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances).</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>35-AMPHOTERICIN-B.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMPHOTERICIN B " rxcui="732">
<ATC code="J02AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZIDOVUDINE" rxcui="11413">
<ATC code="J05AF01" />
<ATC code="J05AR01" />
<ATC code="J05AR04" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the amphotericin B administered intravenously:

increase of the hematological toxicity (addition of effects of bone marrow toxicity)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent CBC.</COMMENT>
</INTERACTION>
</INTERACTIONS>
